Germany COVID-19 Diagnostics Market Size, Share & Trends Analysis Report by Type (Instruments, Reagents & Kits, and Laboratory Testing Services), by Technology Type (PCR Test, Antigen Test, Serology Test, and Rapid/ PoC Test), by Sample Type (Oropharyngeal & Nasopharyngeal Swabs, Blood, Urine, Saliva, and Others), and by End-User (Laboratories, Hospitals, Diagnostic Centers & Clinics, and Research Institutes) and Forecast, 2020-2026
Germany COVID-19 diagnostics market is estimated to see a decline in CAGR of 29.6% during the forecast period. An increase in COVID-19 incidences occurred in several federal states of Germany. The number of COVID-19 cases is rising in the country, with 902 cases confirmed in just one day, since 15th May. A significant trend in the number of tests conducted in laboratories has been reported in the country. As per the Robert Koch Institute (RKI), the cumulative total of samples tested was 8,006,135 was performed in the country, as of 28 July 2020, of which 243,590 tested positive. At Berlin’s Charité hospital, one of the first COVID-19 diagnostic tests was developed, and the German government worked to mobilize the country’s private and public laboratories to quickly scale up testing capacity. Afterward, the country became a pioneer in PCR testing, which continues to feature significantly in the national strategy. In addition, Germany has conducted far more diagnostic swab tests, compared to other European countries, including UK and France (as of 4th August 2020). As a result of the faster spread of COVID-19 in the country, the companies are significantly focusing on launching new accurate, faster, and reliable diagnostic platforms for COVID-19 testing.
Germany COVID-19 diagnostics market is segmented on the basis of technology type, end-use, sample type, and product type. By end-use, the COVID-19 diagnostic market is divided into laboratories, hospitals, diagnostic centers & clinics, and research institutes. By product type, the market is further segmented into instruments, reagents & kits, and laboratory testing services. By Sample type, the market is divided into oropharyngeal & nasopharyngeal swabs, blood, urine, saliva, and others. By technology type, the market is further segmented into PCR Test, Antigen Test, Serology Test, and Rapid/ PoC Test. Among these, the PCR segment has a major share in the COVID-19 diagnostics market. The factor that enhances the PCR test adoption includes a wide availability of tests and generation of the accurate results. However, due to its time consuming and expensive nature, these tests are substituted with other tests such as serology tests.
The companies which are contributing to the growth of the Germany COVID-19 diagnostics market include Siemens Healthineers AG, GA Generic Assays GmbH, gerbion GmbH & Co., KG, GNA Biosolutions GmbH, Intavis Peptide Services GmbH & Co. KG. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups, and technological advancements to stay competitive in the market. For instance, in May 2020, Siemens Healthineers commenced shipping globally total antibody test and molecular test kit for COVID-19 with expanded capacity. Siemens will accelerate its production capacity to over 50 million antibody tests per month with the continuous rise of the pandemic. The company plans to ship over 2.5 million molecular PCR tests per month globally as production capacity expands.
Research Methodology
The market study of the Germany COVID-19 diagnostics market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors.
Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. the analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to the reports.
Secondary Sources Include
The report provides an in-depth analysis of market size, various services offered by the players, and market opportunity. The report will serve as a source for 360-degree analysis of the market delivering insights for making better business decisions.
Market Segmentation
1. Germany COVID-19 Diagnostics Market Research and Analysis by Type
2. Germany COVID-19 Diagnostics Market Research and Analysis by Technology Type
3. Germany COVID-19 Diagnostics Market Research and Analysis by Sample Type
4. Germany COVID-19 Diagnostics Market Research and Analysis by End-User
The Report Covers
Germany COVID-19 diagnostics market is estimated to see a decline in CAGR of 29.6% during the forecast period. An increase in COVID-19 incidences occurred in several federal states of Germany. The number of COVID-19 cases is rising in the country, with 902 cases confirmed in just one day, since 15th May. A significant trend in the number of tests conducted in laboratories has been reported in the country. As per the Robert Koch Institute (RKI), the cumulative total of samples tested was 8,006,135 was performed in the country, as of 28 July 2020, of which 243,590 tested positive. At Berlin’s Charité hospital, one of the first COVID-19 diagnostic tests was developed, and the German government worked to mobilize the country’s private and public laboratories to quickly scale up testing capacity. Afterward, the country became a pioneer in PCR testing, which continues to feature significantly in the national strategy. In addition, Germany has conducted far more diagnostic swab tests, compared to other European countries, including UK and France (as of 4th August 2020). As a result of the faster spread of COVID-19 in the country, the companies are significantly focusing on launching new accurate, faster, and reliable diagnostic platforms for COVID-19 testing.
Germany COVID-19 diagnostics market is segmented on the basis of technology type, end-use, sample type, and product type. By end-use, the COVID-19 diagnostic market is divided into laboratories, hospitals, diagnostic centers & clinics, and research institutes. By product type, the market is further segmented into instruments, reagents & kits, and laboratory testing services. By Sample type, the market is divided into oropharyngeal & nasopharyngeal swabs, blood, urine, saliva, and others. By technology type, the market is further segmented into PCR Test, Antigen Test, Serology Test, and Rapid/ PoC Test. Among these, the PCR segment has a major share in the COVID-19 diagnostics market. The factor that enhances the PCR test adoption includes a wide availability of tests and generation of the accurate results. However, due to its time consuming and expensive nature, these tests are substituted with other tests such as serology tests.
The companies which are contributing to the growth of the Germany COVID-19 diagnostics market include Siemens Healthineers AG, GA Generic Assays GmbH, gerbion GmbH & Co., KG, GNA Biosolutions GmbH, Intavis Peptide Services GmbH & Co. KG. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups, and technological advancements to stay competitive in the market. For instance, in May 2020, Siemens Healthineers commenced shipping globally total antibody test and molecular test kit for COVID-19 with expanded capacity. Siemens will accelerate its production capacity to over 50 million antibody tests per month with the continuous rise of the pandemic. The company plans to ship over 2.5 million molecular PCR tests per month globally as production capacity expands.
Research Methodology
The market study of the Germany COVID-19 diagnostics market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors.
Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. the analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to the reports.
Secondary Sources Include
- Financial reports of companies involved in the market.
- Whitepapers, research-papers, and news blogs.
- Company websites and their product catalog.
The report provides an in-depth analysis of market size, various services offered by the players, and market opportunity. The report will serve as a source for 360-degree analysis of the market delivering insights for making better business decisions.
Market Segmentation
1. Germany COVID-19 Diagnostics Market Research and Analysis by Type
2. Germany COVID-19 Diagnostics Market Research and Analysis by Technology Type
3. Germany COVID-19 Diagnostics Market Research and Analysis by Sample Type
4. Germany COVID-19 Diagnostics Market Research and Analysis by End-User
The Report Covers
- Comprehensive research methodology of the Germany COVID-19 diagnostics market.
- This report also includes a detailed and extensive market overview with key analyst insights.
- An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
- Analysis of regional regulations and other government policies impacting the Germany COVID-19 diagnostics market.
- Insights about market determinants which are stimulating the Germany COVID-19 diagnostics market.
- Detailed and extensive market segments with regional distribution of forecasted revenues.
- Extensive profiles and recent developments of market players.
Table of Contents
1. Report Summary
2. Market Overview and Insights
3. Market Determinants
4. Market Segmentation
5. Company Profiles
Companies Mentioned
A selection of companies mentioned in this report includes:
- Altona Diagnostics GmbH
- ERBA Diagnostics Mannheim GmbH
- GA Generic Assays GmbH
- gerbion GmbH & Co., KG
- GNA Biosolutions GmbH
- Intavis Peptide Services GmbH & Co. KG
- Mikrogen GmbH
- myPOLS Biotec GmbH
- NovaTec Immundiagnostica GmbH
- Siemens Healthineers AG